Oral delivery of purified lipoprotein OspA protects mice from systemic infection with Borrelia burgdorferi

Vaccine
Catherine J LukeAlan G Barbour

Abstract

The lipoprotein outer surface protein A (OspA) of the Lyme disease agent. Borrelia burgdorferi, has provided protection to mice and other animals against systemic infection when delivered orally as a recombinant protein in Escherichia coli, bacille Calmette. Guerin or Salmonella typhimurium. In the present study purified recombinant strain B31 OspA or outer surface protein D (OspD), another lipoprotein of B. burgdorferi, were administered either subcutaneously (s.c.) or orally without cell carrier or adjuvant to mice. In comparison to the OspD preparation, the OspA protein was 256-fold more resistant to trypsin. Whereas OspA in the suspension was in regular complexes of 17-25 nm in size, OspD formed amorphous globules of different sizes. Animals received a primary immunization and at least one booster. Mice immunized s.c. with either OspA or OspD had detectable antibodies to B. burgdorferi by enzyme-linked immunosorbent assay (ELISA), growth inhibition assay (GIA) and immunoblot. Delivered orally, OspA but not OspD elicited a specific antibody response, including IgA, as determined by these assays. The geometric mean titre of sera from mice who received 4 micrograms of OspA orally on days 1, 2, 4, 21 and 22 was 1470 by Ig ELISA...Continue Reading

References

Sep 1, 1992·The Journal of Experimental Medicine·A SădzieneA G Barbour
Jun 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·E FikrigR A Flavell
Dec 1, 1991·The Journal of Infectious Diseases·E FikrigR A Flavell
Jan 1, 1988·Annals of the New York Academy of Sciences·B WilskeM Kramer
May 15, 1986·Experientia·G H WernerP Jollès
Jan 1, 1983·International Archives of Allergy and Applied Immunology·S Nicklin, K Miller
Nov 1, 1982·The Journal of Experimental Medicine·A G BarbourH G Stoenner
Mar 28, 1995·Proceedings of the National Academy of Sciences of the United States of America·T G SchwanP A Rosa
Jan 1, 1993·The Journal of Infectious Diseases·A SadzieneA G Barbour
Jan 1, 1996·The Journal of Experimental Medicine·A M de SilvaE Fikrig
Aug 3, 2013·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·M L K Tang, D J Martino

❮ Previous
Next ❯

Citations

Sep 16, 2011·Clinical and Vaccine Immunology : CVI·Luciana Meirelles RicherMaria Gomes-Solecki
Jul 11, 2007·Infection and Immunity·Xin LiErol Fikrig
Dec 21, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jean I TsaoAlan G Barbour
Oct 14, 2014·Frontiers in Cellular and Infection Microbiology·Maria Gomes-Solecki
Jul 18, 2008·Clinical and Vaccine Immunology : CVI·Beatriz del RioMaria Gomes-Solecki
Jan 19, 2020·Applied Microbiology and Biotechnology·Martin StrnadRyan O M Rego

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.